Partner/Funding
Two consecutive projects have been funded by the Swiss National Science Foundation (SNSF grants no. 160195 and no. 189341) to develop a cell-based non-viral gene therapy to treat dry AMD similarly to the TargetAMD 1.0 approach for wet AMD.
Target Dry AMD
Only one therapy exists for the dry form of AMD, which – however — concerns about 90% of patients suffering from AMD in total. This drug, Syfovre®, is currently available only in the United States and shows a similar administration route and frequency as drugs for wet AMD, thus, shows comparable drawbacks.
Target Dry AMD
The Target Dry AMD approach is a progression of TargetAMD 1.0 applying the same treatment approach (subretinal injection of autologous genetically modified Iris Pigment Epithelial cells) and technology for genetic modification (non-viral Sleeping Beauty transposon system).
